Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
Capital International Investors filed an amended Schedule 13G reporting its beneficial ownership of common stock of CRISPR Therapeutics AG. The firm is deemed to beneficially own 1,186,794 shares, representing 1.2% of the issuer’s 95,300,233 shares believed to be outstanding.
Capital International Investors reports sole voting and sole dispositive power over all reported shares and no shared power. The filer also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of CRISPR Therapeutics AG.
CRISPR Therapeutics’ Chief Medical Officer, Naimish Patel, reported buying 1,508 common shares at $32.96 each on April 3, 2025. This direct ownership transaction brought his total reported holdings to 1,508 shares.
The filing notes this purchase was matchable under Section 16(b) with a later sale of 1,508 shares at $35.94 per share on May 29, 2025 under a mandatory “sell to cover” for a vested restricted stock unit. Patel agreed to pay CRISPR Therapeutics $4,493.84, equal to the full short-swing profit.
CRISPR Therapeutics’ Chief Financial Officer Prasad Raju reported an option exercise and share sale. On January 22, 2026, he exercised a stock option for 34,972 Common Shares at an exercise price of $45.15 per share, acquiring the same number of common shares. That same day, he sold 34,972 Common Shares at a weighted average price of $60.19 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025. After these transactions, he directly held 6,767 Common Shares and 41,667 stock options.
CRISPR Therapeutics Chief Executive Officer and director Samarth Kulkarni reported multiple open-market sales of common shares under a pre-set Rule 10b5-1 trading plan adopted on August 27, 2025. On January 20, 2026, he sold 21,433 common shares at a weighted average price of $51.61 and 8,567 common shares at a weighted average price of $52.10. On January 22, 2026, he sold 60,000 common shares at a weighted average price of $60.23. Following these transactions, Kulkarni beneficially owns 134,201 common shares directly and 85,622 common shares indirectly through The Kulkarni 2023 GRAT.
CRISPR Therapeutics-related Form 144 shows planned insider share sales. Dr. Samarth Kulkarni has filed notice to sell 60,000 shares of common stock through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $3,648,600. The filing notes that 48,081 shares were acquired on 10/16/2025 and 11,919 shares on 08/15/2025, both as restricted stock awards from the issuer, treated as compensation. It also discloses that during the past three months, Dr. Kulkarni sold 30,000 common shares on 01/20/2026 for gross proceeds of $1,552,593. Shares of the issuer’s common stock outstanding are listed as 95,300,233.
A shareholder filed a Rule 144 notice to sell 34,972 shares of common stock through Morgan Stanley Smith Barney on or about January 22, 2026 on NASDAQ. The planned sale has an aggregate market value of $2,105,069.60.
The shares to be sold were acquired on January 22, 2026 via a stock option exercise, paid for in cash. Shares of the issuer outstanding were 95,300,233 at the time of the notice; this is a baseline figure, not the amount being sold.
Over the prior three months, the same seller, Raju Prasad, reported additional common share sales of 10,000 shares for $559,548.00 on December 22, 2025 and 29,700 shares for $1,786,635.87 on January 6, 2026.
A holder of common stock in CRSP has filed a notice of proposed resale under Rule 144. The filing covers the planned sale of 30,000 shares of common stock through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $1,578,300. The shares are part of a larger base of 95,300,233 common shares outstanding.
The securities to be sold were acquired as compensation through restricted stock awards from the issuer in multiple grants dated between 2018 and 2025, each labeled as compensation on the acquisition and payment dates. The person for whose account the sale is to be made represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
CRISPR Therapeutics AG filed an update on multiple gene-editing programs across cardiovascular, autoimmune, oncology and regenerative medicine. The company highlighted continued progress with its in vivo programs using a proprietary lipid nanoparticle delivery platform, including CTX310, which in 2025 showed deep and durable reductions in triglycerides and LDL after a single intravenous dose with a well‑tolerated safety profile and has moved into Phase 1b trials.
CTX320, targeting LPA, has shown reductions of up to 73% in a dose‑escalation trial, while next‑generation candidate CTX321 with about two‑fold greater preclinical potency is in IND/CTA‑enabling studies. Additional preclinical assets include CTX460 for alpha‑1 antitrypsin deficiency and CTX340 for refractory hypertension. Zugocabtagene geleucel (zugo‑cel) is in Phase 1 autoimmune trials where early systemic lupus erythematosus patients achieved drug‑free remission or full score improvement, and an oncology trial is ongoing alongside a new collaboration with Eli Lilly. In regenerative medicine for diabetes, CTX211 data with detectable C‑peptide at 12 months support a move to next‑generation candidate CTX213.
CRISPR Therapeutics AG’s Chief Financial Officer, Prasad Raju, reported option exercises and share sales in Common Shares. On January 6, 2026, he exercised stock options to acquire 23,361 Common Shares at an exercise price of $45.15 and another 6,339 Common Shares at $44.31. After these transactions, he directly held 30,128 and 36,467 Common Shares, respectively, from the two exercises.
The same day, he reported open-market sales of Common Shares in multiple transactions, including 18,933 shares at a weighted average price of $60.1799 and additional sales at weighted average prices of $60.00 and $60.2134, leaving him with 6,767 Common Shares directly held after the final sale. The filing states these sales were made under a Rule 10b5-1 trading plan adopted on August 18, 2025. The derivative table shows remaining stock options outstanding with expirations in 2033 and vesting schedules described in the footnotes.
Raju Prasad filed a notice of proposed sale of the issuer’s common stock under Rule 144. The planned transaction covers 29,700 common shares, to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $1,786,635.87, based on information in the filing. The shares relate to a stock option exercise on 01/06/2026, paid in cash the same day, and are expected to be sold around 01/06/2026 on the NASDAQ market, where 95,300,233 shares of this class are outstanding.
The filing also reports that over the prior three months, Prasad sold 10,000 common shares on 12/22/2025 for $559,548.00. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.